The company was founded in 1963 by Dr. Alain Mérieux, who aimed to improve public health by combating infectious diseases. Initially focused on the development of diagnostic tests for infectious diseases, bioMérieux gradually expanded its product portfolio to cover a wide range of medical conditions.

The company offers a comprehensive range of products and services, including automated systems, reagents, instruments, and software solutions for clinical diagnostics, industrial microbiology, and antimicrobial resistance management. Their innovative diagnostic solutions address major public health concerns such as bloodstream infections, respiratory infections, sepsis, or food safety. Operating on a global scale, bioMérieux has established a strong presence in over 160 countries.

The company has an extensive network of subsidiaries, joint ventures, and partnerships worldwide. Notable subsidiaries include bioMérieux Inc. Additionally, bioMérieux collaborates with various academic institutions, research organizations, and industry partners to advance medical diagnostics and drive innovation.

bioMérieux holds a prominent position in the global market for in vitro diagnostics. The company's annual sales have consistently increased over the years, reaching €2. 7 billion in 2020.

With a focus on research and development, bioMérieux invests heavily in technological advancements and product innovation, maintaining its competitive edge in the diagnostic industry. The company places a strong emphasis on sustainable development and has implemented eco-friendly initiatives throughout its operations. In recent years, bioMérieux has achieved significant milestones, including the acquisition of pre-analytics specialist Wasatch Microfluidics and the launch of the BioFire Respiratory Panel 2.

1, which detects multiple pathogens responsible for respiratory infections. These strategic moves and product developments have enhanced bioMérieux's product lineup and further solidified its position in the market. As of the latest available information, bioMérieux continues to lead the field of IVD and remains committed to addressing global health challenges.

The company actively responds to emerging infectious diseases and has played a critical role in the fight against the COVID-19 pandemic, developing diagnostics and supporting testing efforts around the world